Lannett Company, Inc. LCI today announced that the U.S. Food and Drug Administration has approved the company's 505(b)(2) New Drug Application for Morphine Sulfate Oral Solution on June 23, 2011. Sales of Morphine Sulfate Oral Solution for the last 12 months at Average Wholesale prices were approximately $31.7 million, according to Wolters Kluwer.
The company expects to commence shipping the product shortly.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in